Dexlansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for use in patients 12 years of age and older for the healing of all grades of erosive esophagitis (EE), the maintenance of healed EE and relief of heartburn, as well as the treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD).
Dexlansoprazole Delayed-Release Capsules (30 mg and 60 mg) have an estimated market size of $285 million for the twelve months ending September 2025, according to IQVIA.
With this approval, Alembic now holds a cumulative total of 229 ANDA approvals (including 209 final approvals and 20 tentative approvals) from the USFDA.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.
The company’s consolidated net profit jumped 20.40% to Rs 184.71 crore in Q2 FY26, compared to Rs 153.41 crore posted in Q2 FY25. Revenue from operations grew 15.90% year on year (YoY) to Rs 1,910.15 crore in the quarter ended 30 September 2025.
The counter rose 0.53% to currently trade at Rs 922 on the BSE.
"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."